keyword
MENU ▼
Read by QxMD icon Read
search

Tolvaptan

keyword
https://www.readbyqxmd.com/read/29789986/optimal-equation-for-estimation-of-glomerular-filtration-rate-in-autosomal-dominant-polycystic-kidney-disease-influence-of-tolvaptan
#1
Tsuyoshi Yamaguchi, Eiji Higashihara, Takatsugu Okegawa, Isao Miyazaki, Kikuo Nutahara
BACKGROUND: The reliability of various equations for estimating the GFR in ADPKD patients and the influence of tolvaptan on the resulting estimates have not been examined when GFR is calculated on the basis of inulin clearance. METHODS: We obtained baseline and on-tolvaptan measured GFRs (mGFRs), calculated on the basis of inulin clearance, in 114 ADPKD, and these mGFRs were compared with eGFRs calculated according to four basic equations: the MDRD, CKD-EPI, and JSN-CKDI equations and the Cockcroft-Gault formula, as well as the influence of tolvaptan and of inclusion of cystatin C on accuracy of the results...
May 22, 2018: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/29760305/enhancement-of-warfarin-anticoagulant-reaction-in-patients-with-repeated-oral-tolvaptan-administration
#2
Masayuki Saito, Masayoshi Ajioka, Takahiro Iwao, Tadashi Suzuki
The pharmacokinetics and pharmacodynamics of warfarin remained unaffected by tolvaptan during clinical trials. However, tolvaptan prolonged the prothrombin time-international normalized ratio (PT-INR) level of patients with cardiovascular disease taking warfarin. Tolvaptan was prescribed to 576 patients from December 2010 to December 2015. Of these patients, 37 underwent anticoagulant therapy. We investigated PT-INR fluctuation immediately before tolvaptan therapy was initiated. PT-INR remained unchanged in the control group and in groups administered with less than 7...
May 11, 2018: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/29751971/cardiac-hypertrophy-elevates-serum-levels-of-fibroblast-growth-factor-23
#3
Isao Matsui, Tatsufumi Oka, Yasuo Kusunoki, Daisuke Mori, Nobuhiro Hashimoto, Ayumi Matsumoto, Karin Shimada, Satoshi Yamaguchi, Keiichi Kubota, Sayoko Yonemoto, Tomoaki Higo, Yusuke Sakaguchi, Yoshitsugu Takabatake, Takayuki Hamano, Yoshitaka Isaka
Several experimental studies have shown that fibroblast growth factor 23 (FGF23) induces left ventricular hypertrophy (LVH). However, the opposite directional relationship, namely a potential effect of LVH on FGF23, remains uncertain. Here we evaluated the effects of LVH on FGF23 using cardiomyocyte-specific calcineurin A transgenic mice. At six weeks, these mice showed severe LVH, with elevated levels of serum intact FGF23. FGF23 levels were elevated in cardiomyocytes, but not osteocytes, of the transgenic animals...
May 8, 2018: Kidney International
https://www.readbyqxmd.com/read/29743456/-short-term-sustained-virological-response-in-a-patient-with-liver-cirrhosis-hepatitis-c-and-declining-hepatic-spare-ability-during-treatment-with-direct-acting-antivirals
#4
Hitoshi Mori, Hiroaki Takaya, Tadashi Namisaki, Ryuichi Noguchi, Junichi Hanatani, Miki Kaneko, Kenichiro Seki, Yasushi Okura, Mitsuteru Kitade, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji
A 75-year-old female patient with liver cirrhosis and hepatitis C was treated with direct-acting antivirals (DAA) (Sofosbuvir+Ledipasvir). The hepatitis C virus (HCV) -RNA level decreased to negative 4 weeks after the start of the treatment. Six weeks later, she developed ascites and showed declining hepatic spare ability. Accordingly, DAA treatment was stopped. She was started on furosemide 20mg/day and spironolactone 50mg/day. After 7 days, she started taking tolvaptan 7.5mg/day because furosemide and spironolactone proved to be ineffective...
2018: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/29731121/sudden-death-after-hospitalization-for-heart-failure-with-reduced-ejection-fraction-from-the-everest-trial
#5
Muthiah Vaduganathan, Ravi B Patel, Robert J Mentz, Haris Subacius, Neal A Chatterjee, Stephen J Greene, Andrew P Ambrosy, Aldo P Maggioni, James E Udelson, Karl Swedberg, Marvin A Konstam, Christopher M O'Connor, Javed Butler, Mihai Gheorghiade, Faiez Zannad
Patients with chronic heart failure with reduced ejection fraction (HFrEF) benefit from medical and device therapies targeting sudden cardiac death (SCD). Contemporary estimates of SCD risk after hospitalization for heart failure are limited. We describe the incidence, timing, and clinical predictors of SCD after hospitalization for HFrEF (≤40%) in the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial. Multiple logistic regression analyses tested >30 baseline covariates (including treatment randomization, demographics, comorbid conditions, natriuretic peptides, ejection fraction, and medical and device therapies) to identify predictors of 1-year SCD...
April 11, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29703048/tolvaptan-rescue-contrast-induced-acute-kidney-injury-a-case-report
#6
Wei-Chieh Lee, Hsiu-Yu Fang, Chih-Yuan Fang
RATIONALE: Contrast-induced acute kidney injury is one of the most serious adverse effects of contrast media and is related to three distinct but interacting mechanisms: medullary ischemia, formation of reactive oxygen species and direct tubular cell toxicity, especially in the patients with chronic kidney disease. The strategies of treatment, including stabilization of hemodynamic parameters and maintenance of normal fluid and electrolyte balance, were similar to the management of other types of acute kidney injury...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29692992/tolvaptan-for-primary-aldosteronism-and-autosomal-dominant-polycystic-kidney-disease-a-case-report
#7
Kyohei Kunizawa, Junichi Hoshino, Hiroki Mizuno, Tatsuya Suwabe, Keiichi Sumida, Masahiro Kawada, Masayuki Yamanouchi, Akinari Sekine, Noriko Hayami, Rikako Hiramatsu, Eiko Hasegawa, Naoki Sawa, Kenmei Takaichi, Shigeru Shibata, Yoshifumi Ubara
A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years. At the age of 58, tolvaptan was started (60 mg/day) to treat her renal disease. After 8 months of tolvaptan therapy, hypokalemia-related muscle weakness became prominent, and hypertension became refractory. Finally, treatment with low-dose tolvaptan (30 mg/day) and high-dose spironolactone (100 mg/day) normalized serum potassium and the blood pressure...
January 2018: Case Reports in Nephrology and Dialysis
https://www.readbyqxmd.com/read/29687159/the-effects-of-tolvaptan-dose-on-cardiac-mortality-in-patients-with-acute-decompensated-heart-failure-after-hospital-discharge
#8
Kenji Matsumoto, Shoichi Ehara, Yasuhiro Nakamura, Keiko Otsuka, Yoshio Kawase
Tolvaptan (TLV) is a newly developed oral vasopressin-2 receptor antagonist that is mostly used for patients with acute decompensated heart failure (ADHF) refractory to conventional diuretic therapy. The aim of this study was to investigate the effects of outpatient TLV dose on cardiac mortality in patients discharged after hospitalization for ADHF. One hundred and five patients with ADHF who had been treated with TLV for the first time during hospitalization were retrospectively divided into three groups based on outpatient TLV use and dose...
April 23, 2018: Heart and Vessels
https://www.readbyqxmd.com/read/29671146/validation-trial-for-efficacy-of-ultrasonographic-measurement-method-to-predict-ascitic-volume-using-virtual-ultrasonography
#9
Masashi Hirooka, Yohei Koizumi, Yusuke Imai, Atsushi Yukimoto, Takao Watanabe, Osamu Yoshida, Masanori Abe, Yoichi Hiasa
PURPOSE: The aim of this study was to clarify whether ultrasound quantitative methods were positively correlated with volume of ascites evaluated by whole abdominopelvic CT. METHODS: Sixty-eight patients with cirrhotic ascites were retrospectively analyzed. First, to confirm that virtual ultrasonography (VUS) is an alternative method to conventional ultrasound, 22 patients underwent both conventional ultrasonography and VUS. Second, the efficacy of US quantitative methods (3-point method, 4-point method, 5-point method, and Matsumoto's method) was confirmed by VUS in 68 patients...
April 18, 2018: Journal of Medical Ultrasonics
https://www.readbyqxmd.com/read/29665203/tolvaptan-alleviates-excessive-fluid-retention-of-nephrotic-diabetic-renal-failure-unresponsive-to-furosemide
#10
Tesshu Takada, Tsuguto Masaki, Ayako Hoshiyama, Takuya Toki, Yuji Kamata, Masayoshi Shichiri
Patients with diabetic nephropathy develop nephrotic syndrome, and may show limited response to conventional therapy. They often require earlier initiation of renal replacement therapy because they become refractory to diuretics, and experience excessive fluid retention. We aimed to investigate the efficacy of tolvaptan, an oral arginine vasopressin type 2 receptor antagonist, in a case series of 14 severe diabetic renal failure patients who were severely refractory to maximal doses of furosemide and had excessive fluid retention despite preserved cardiac function and residual renal function...
April 17, 2018: Nephrology
https://www.readbyqxmd.com/read/29629516/safety-and-efficacy-of-tolvaptan-in-korean-patients-with-hyponatremia-caused-by-the-syndrome-of-inappropriate-antidiuretic-hormone
#11
Sang Woong Han, Joo Hark Yi, Kyung Pyo Kang, Ha Yeon Kim, Soo Wan Kim, Hoon Young Choi, Sung Kyu Ha, Gheun Ho Kim, Yang Wook Kim, Kyung Hwan Jeong, Sug Kyun Shin, Ho Jung Kim
BACKGROUND: The aim of this multicenter study was to evaluate the safety and efficacy of tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). METHODS: Of 51 enrolled patients with SIADH, 39 patients (16 female patients, aged 70.8 ± 11.3 years) were included in an intention to treat analysis. All patients received 15 mg/day as the initial dose, and the dose was then increased up to 60 mg/day (as needed) until day 4...
April 9, 2018: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/29607963/association-between-the-serum-sodium-levels-and-the-response-to-tolvaptan-in-liver-cirrhosis-patients-with-ascites-and-hyponatremia
#12
Manabu Hayashi, Kazumichi Abe, Masashi Fujita, Ken Okai, Atsushi Takahashi, Hiromasa Ohira
Objective Hyponatremia is closely associated with the pathophysiology of cirrhosis. However, the association between the serum sodium level and the response to tolvaptan is unclear. This study evaluated the factors related to the tolvaptan response and the prognosis in cirrhosis patients with ascites and hyponatremia. Methods We retrospectively reviewed the clinical records of cirrhosis patients hospitalized for treatment with tolvaptan. The associations of patient baseline characteristics with the tolvaptan response after one week and of the characteristics after one-month tolvaptan treatment with the prognosis were analyzed...
March 30, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29607892/novel-risk-score-efficiently-prevents-tolvaptan-induced-hypernatremic-events-in-patients-with-heart-failure
#13
Koichiro Kinugawa, Naoki Sato, Takayuki Inomata, Moriyoshi Yasuda, Yoshiyuki Shibasaki, Toshiyuki Shimakawa
BACKGROUND: It has been 7 years since tolvaptan was approved in Japan for the indication of heart failure in patients with volume overload; the drug can be used in patients with normonatremia. Hypernatremia was identified as a significant adverse event to be prevented.Methods and Results:We compiled and analyzed data from 3,349 patients over 5 years to identify patients at high risk of hypernatremia with tolvaptan treatment. The incidence of hypernatremia, defined as serum sodium ≥150 mEq/L, was 3...
April 25, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29607790/protective-effects-of-diuretics-against-development-of-cardiovascular-disease-in-patients-with-chronic-kidney-disease-systematic-review
#14
Akinori Aomatsu, Susumu Ookawara, Kenichi Ishibashi, Yoshiyuki Morishita
Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with chronic kidney disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including pre-dialysis, hemodialysis, and peritoneal dialysis...
April 2, 2018: Cardiovascular & Hematological Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29602756/tolvaptan-for-heart-failure-in-chronic-kidney-disease-patients-a-systematic-review-and-meta-analysis
#15
REVIEW
Jonathan Sen, Erin Chung, Darryl McGill
BACKGROUND: Heart failure (HF) is frequently associated with renal impairment. Tolvaptan is reported to be effective in treating congestion in HF without significant electrolyte loss compared to conventional diuretics. However, the safety and efficacy of its use in patients with chronic kidney disease (CKD) is uncertain. This systematic review and meta-analysis evaluated the efficacy and safety outcomes of tolvaptan for HF management in patients with CKD, with a focus at a physiologic basis related to safety...
February 13, 2018: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/29575630/isosorbide-dinitrate-in-nephronophthisis-treatment
#16
Alanna Strong, Samina Muneeruddin, Richard Parrish, Daniel Lui, Susan B Conley
Nephronophthisis is a progressive disease that affects development of the renal tubules and leads to end stage renal disease. Many affected children have isolated renal disease; however, there can be additional manifestations including heart defects, liver fibrosis, brain malformations, and situs inversus. There is no way to slow or modify the disease. We describe a patient who presented at birth with cholestatic jaundice and decreased kidney function, found by exome sequencing to have two NPHP3 variants. Her clinical status deteriorated rapidly, and two disease-modifying agents were given in hopes of slowing disease progression, the arginine vasopressin type II receptor antagonist tolvaptan to stabilize her renal function and isosorbide dinitrate to manage her poorly controlled hypertension...
April 2018: American Journal of Medical Genetics. Part A
https://www.readbyqxmd.com/read/29571442/wyatt-cm-le-meur-y-reprise-tolvaptan-in-advanced-polycystic-kidney-disease-kidney-int-2018-93-292-295
#17
(no author information available yet)
No abstract text is available yet for this article.
April 2018: Kidney International
https://www.readbyqxmd.com/read/29566934/comparison-of-two-dosing-methods-for-immediate-administration-of-tolvaptan-in-acute-decompensated-heart-failure
#18
Mitsutoshi Oguri, Hideki Ishii, Shiou Ohguchi, Kunihiko Takahara, Yoshihiro Kawamura, Yuki Yokoi, Kazuhiro Izumi, Hiroshi Takahashi, Haruo Kamiya, Toyoaki Murohara
BACKGROUND: The clinical dosing method for tolvaptan in patients with acute heart failure (HF) is still unclear. We aimed to compare the differences in clinical effect between two dosing regimens: once-daily 7.5mg and twice-daily 3.75mg. METHODS: In this randomized trial, tolvaptan was administered within 12h from hospital admission. The primary outcome was the serial change in congestion scores measured every day from enrollment until dosing day 7. Outcomes including safety parameters were also evaluated...
March 19, 2018: Journal of Cardiology
https://www.readbyqxmd.com/read/29557615/-tolvaptan-in-a-pediatric-cardiorenal-syndrome-what-is-its-role
#19
M Angeles Tejero Hernández, Elena García Martínez, M José Arroyo Marin, Elena Gómez Guzmán
The cardiorenal syndrome has been defined as a situation in which therapy to relieve congestive symptoms of heart failure is limited by a decreased renal function. The resistance to conventional diuretic treatment makes difficult managing these patients. Tolvaptan, a selective vasopressin-2 receptor antagonist, has been used successfully in adults with this pathology but the experience with children is very limited. A five-year-old girl with renal failure waiting for a heart transplant is presented. Tolvaptan (0...
April 1, 2018: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/29508162/elevation-of-the-serum-liver-enzyme-levels-during-tolvaptan-treatment-in-patients-with-autosomal-dominant-polycystic-kidney-disease-adpkd
#20
Shiho Makabe, Toshio Mochizuki, Michihiro Mitobe, Yumi Aoyama, Hiroshi Kataoka, Ken Tsuchiya, Kosaku Nitta
BACKGROUND: In 2014, tolvaptan, a vasopressin receptor antagonist, was approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD) in Japan. Clinical trials of tolvaptan revealed frequent occurrence of the liver function abnormality. According to the package insert in Japan, liver function tests should be performed once a month in patients receiving tolvaptan. Furthermore, immediate discontinuation of tolvaptan is recommended in the appearance of liver function abnormalities...
March 5, 2018: Clinical and Experimental Nephrology
keyword
keyword
3017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"